Cook Medical files for US approval of Zilver PTX
This article was originally published in Clinica
Executive Summary
Cook Medical (Bloomington, Indiana) has submitted a premarket approval (PMA) application to the US FDA for Zilver PTX, its drug-eluting peripheral stent. Intended for use in patients with peripheral arterial disease in the superficial femoral artery, Zilver PTX is a polymer-free Nitinol stent that elutes paclitaxel. The PMA submission includes data from the ongoing Zilver PTX clinical trial, data from which were reported at EuroPCR last month (www.clinica.co.uk, 7 June 2010). PAD is thought to affect eight million people over the age of 40 in the US.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.